• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Acta Paediatr . Benign course and clinical features of COVID-19 in hospitalised febrile infants up to 60 days old

tetano

Editor, Senior Moderator
Acta Paediatr


. 2021 Jun 18.
doi: 10.1111/apa.15993. Online ahead of print.
Benign course and clinical features of COVID-19 in hospitalised febrile infants up to 60 days old


Havazelet Bilavski Yarden[SUP] 1 [/SUP], Sarit Balanson[SUP] 1 [/SUP], Ranaa Damouni Shalabi[SUP] 2 [/SUP], Halima Dabaja-Younis[SUP] 2 [/SUP], Galia Grisaru-Soen[SUP] 3 [/SUP], Ilan Youngster[SUP] 4 [/SUP], Daniel Glikman[SUP] 5 [/SUP], Shalom Ben Shimol[SUP] 6 [/SUP], Eli Somech[SUP] 7 [/SUP], Diana Tasher[SUP] 8 [/SUP], Michal Stein[SUP] 9 [/SUP], Giora Gottesmanm[SUP] 10 [/SUP], Gilat Livni[SUP] 1 [/SUP]



Affiliations

Abstract

Aim: Minimal data exist regarding the severity of COVID-19 in febrile infants under 60 days old. This multicentre prospective study explored the clinical course and outcomes of this hospitalised patient population, as, to date, the best approach has not been specifically addressed.
Methods: This study focused on the clinical features, laboratory parameters and outcomes of febrile infants up to 60 days old who tested positive for the virus and were hospitalised in Israel from March 2020 to January 2021. The data were extracted from a real-time prospective surveillance network for COVID-19 that includes 20 of the country's 26 hospitals.
Results: We identified 75 febrile young infants (60% female) with COVID-19 at a median age of 28 days (range 8-56 days). Of these, 84% had an unremarkable medical history, 29% had respiratory symptoms and 96% had a mild illness. The Rochester criteria showed that 44% were considered at high-risk for serious bacterial infections and we found that eight infants actually had concomitant bacterial infections. Outcomes were excellent and no complications or fatalities were reported CONCLUSION: The excellent outcomes of young febrile infants with COVID-19 closely resembled other respiratory viral aetiologies of fever in this age group and there were no fatalities.

Keywords: COVID-19; Rochester criteria; infants; neonatal fever; serious bacterial infection.
 
Back
Top Bottom